Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Portales, F. [1 ]
Philip, P. A. [2 ]
Hammel, P. [3 ]
Buscaglia, M. [4 ]
Pazo-Cid, R. [5 ]
Manzano Mozo, J. L. [6 ]
Kim, E. S. [7 ]
Dowden, S. [8 ]
Zakari, A. [9 ]
Borg, C. [10 ]
Terrebonne, E. [11 ]
Rivera Herrero, F. [12 ]
Li, J. Shiansong [13 ]
Ong, T. J. [14 ]
Nydam, T. [14 ]
Lacy, J. [15 ]
机构：
[1] Inst Reg Canc Montpellier ICM, Digestif, Montpellier, France
[2] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[3] Hop Beaujon, Gastroenterol, Clichy, France
[4] Azienda Osped Univ San Martino, Med Oncol, Genoa, Italy
[5] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
[6] Hosp Badalona Germans Trias & Pujol, Med Oncol, Barcelona, Spain
[7] Levine Canc Inst, Med Oncol, Charlotte, NC USA
[8] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[9] Florida Hosp Canc Inst, Gastro Intestinal Canc Program, Orlando, FL USA
[10] Ctr Hosp Belfort Montbeliard, Med Oncol, Montbeliard, France
[11] Hosp Haut Leveque, Med Oncol, Giround, France
[12] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[13] Celgene Corp, Biostat, Summit, NJ USA
[14] Celgene Corp USA, Med Affairs, Summit, NJ USA
[15] Yale Canc Ctr, Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
730P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
    Chiorean, E. G.
    Cheung, W. Y.
    Giordano, G.
    Kim, G.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
  • [22] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
    Chan, Edmond Mankee
    Hong, Theodore S.
    Clark, Jeffrey William
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Zhu, Andrew
    Goyal, Lipika
    Murphy, Janet E.
    Kwak, Eunice L.
    Wo, Jennifer Y.
    Ryan, David P.
    Faris, Jason Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [23] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
    Hochster, Howard S.
    Wainberg, Zev A.
    Gutierrez, Martin
    Waterhouse, David
    Chiorean, E. Gabriela
    George, Ben
    Ko, Amy
    Manax, Victoria
    Stergiopoulos, Sotirios
    O'Dwyer, Peter
    CANCER RESEARCH, 2016, 76
  • [24] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [25] Quality of life (QoL) in elderly patients (pts) with advanced NSCLC treated with nab-paclitaxel (nab-P) plus carboplatin (C): Interim results from the ABOUND. 70+study
    Weiss, J.
    Kim, E.
    Amiri, K. I.
    Anderson, E.
    Dakhil, S.
    Haggstrom, D.
    Jotte, R.
    Konduri, K.
    Modiano, M.
    Ong, T. J.
    Sanford, A.
    Smith, D.
    Socoteanu, M.
    Goldman, J.
    Langer, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
    Tempero, Margaret A.
    Reni, Michele
    Riess, Hanno
    Pelzer, Uwe
    O'Reilly, Eileen Mary
    Winter, Jordan Michael
    Oh, Do-Youn
    Li, Chung-Pin
    Tortora, Giampaolo
    Chang, Heung-Moon
    Lopez, Charles D.
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Ferrara, Stefano
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
    Sahai, Vaibhav
    Tabernero, Josep
    Van Cutsem, Eric
    Reni, Michele
    Tempero, Margaret A.
    O'Reilly, Eileen Mary
    Berlin, Jordan
    Riess, Hanno
    Goldstein, David
    Li, Mingyu
    Lu, Brian
    Ferrara, Stefano
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [29] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [30] Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heavily pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis
    Febbraro, Antonio
    Zaniboni, Alberto
    Zagonel, Vittorina
    Di Costanzo, Francesco
    Malorino, Luigi
    Bertocchi, Paola
    Bergamo, Francesca
    Glommonl, Ellsa
    Giordano, Guida
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345